{
    "nctId": "NCT05189067",
    "briefTitle": "Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer",
    "officialTitle": "A Single-center, Prospective, Randomized Study of Adjuvant Paclitaxel and Trastuzumab Versus Docetaxel and Trastuzumab in Stage I HER2 Positive Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "HER2-positive Breast Cancer, Adjuvant Therapy",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2, PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 190,
    "primaryOutcomeMeasure": "disease free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female aged 18 - 70 years old;\n2. The histopathological confirm of invasive breast cancer;\n3. HER-2 positive: immuno-histochemistry (IHC) 3+ or fluorescence in situ hybridization (FISH) confirmed amplification of erbb2 gene;\n4. Tumor must be \u2264 2cm in greatest dimension, negative axillary lymph node or with micrometastasis (axillary nodes with tumor clusters \u2264 0.2cm);\n5. No more than 90 days from the patient's most recent breast surgery for this breast cancer;\n6. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1;\n7. Adequate bone marrow function: neutrophil \u2265 1500/mm\\^3, hemoglobin \u2265 9 g/dl, and platelets \u2265 100,000/mm\\^3;\n8. Adequate liver and renal function: creatinine \u2264 1.5 folds of the upper limit of normal value; aspartate aminotransferase and alanine aminotransferase \u2264 1.5 folds of the upper limit of normal value, aspartate aminotransferase and alanine aminotransferase \u2264 2 folds of the upper limit of normal value for patient with Gilbert 's syndrome;\n9. Left ventricular ejection fraction (LVEF) \u2265 50%;\n10. Willing and able to sign informed consent.\n\nExclusion Criteria:\n\n1. Any of the following due to teratogenic potential of chemotherapy: pregnant women, nursing women, women of childbearing potential who are unwilling to employ adequate contraception;\n2. Locally advanced tumors at diagnosis, including tumors fixed to the chest wall, peau d'orange, skin ulcerations/nodules, or clinical inflammatory changes;\n3. History of prior chemotherapy in the past 5 years;\n4. History of prior trastuzumab therapy;\n5. Patients with a history of previous invasive breast cancer;\n6. Active, unresolved infection;\n7. Prior history of any other malignancy in the past 5 years, except for early stage tumors of the skin or cervix treated with curative intent;\n8. Can not tolerate or be allergic to chemotherapy, anti-HER-2 therapy or pharmaceutical materials such as benzyl alcohol;\n9. \u2265 grade 2 neuropathy;\n10. Active cardiac disease: Any prior myocardial infarction (asymptomatic changes on EKG suggestive of old myocardial infarction is not an exclusion); Documented congestive heart failure (CHF); Current use of any therapy specifically for CHF; Current uncontrolled hypertension (diastolic \\>100 mmHg or systolic \\> 200 mmHg); Clinically significant pericardial effusion;\n11. The antibody of hepatitis C virus, HIV or Treponema pallidum positive; HBsAg positive and hepatitis B virus DNA in peripheral blood \u2265 10\\^3 copy/mL\uff1b\n12. Enrollment on other Investigational studies within 30 days;\n13. Not allowed by the investigators.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}